N/A N=99 Veterans Intensive Personalized Treatment in Heart Failure
Heart Failure
Primary: Medication Adherence (Refill Compliance for All HF Medications) — 0.94; 0.97; 0.99 proportion of refill compliance — p=0.1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=646 Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Multiple Myeloma
Primary: Time to Progression (TTP) — 6.5; 9.3 Months
N/A N=376 Pulp Capping With Two Different Agents
Dental Pulp Exposure
Primary: Tooth Survival — 158; 130 participants — p=.046
Phase 2 N=68 BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment
Leukemia, Myeloid, Acute
Primary: The Maximum Tolerated Dose (MTD) of 2 Schedules of BI 811283 in Combination With Cytarabine. — 100; NA mg
N/A N=43 Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 0.22; 0.18 units on a scale
Phase 2 N=23 Yoga Cancer Rehabilitation Study: A Randomized Trial of Adaptive Yoga for Older Cancer Survivors
Neoplasms
Primary: Patient-Reported Outcomes Measurement System Scale, a Scale Developed by the National Institute of Health to Assess Outcomes Across Different Trials. — 8.90; 12.26…
Phase 2 N=30 Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
Hypoxic Ischemic Encephalopathy
Primary: The Pharmacokinetic Profile of Darbe After the First Dose During Cooling — 180,866; 26,555 AUC (h*mU/L) — p=0.006
Phase 1 N=25 A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)
Type 2 Diabetes Mellitus
Primary: Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2 — 6; 7; 10; 12 Participants
Phase 3 N=80 Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight
Obesity
Primary: Changes in Body Fat Mass — 16790.27; 18223.75; 20174.10; 21474.88 g
N/A N=350 Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit
Cross Infection · Pneumonia, Ventilator-associated · Catheter-related Infections
Primary: Incidence of Nosocomial Infection — 15; 30 participants — p=0.049
Phase 2 N=60 Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Breast Cancer · Male Breast Cancer · Stage II Breast Cancer
Primary: Pathologic Complete Response Rate (pCR) — 33 participants
Phase 2 N=298 Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Ovarian · Breast · Prostate
Primary: Tumour Response Rate — 12.9; 31.1; 21.7; 50 Percentage of participants
Phase 4 N=222 Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
Postherpetic Neuralgia ( PHN )
Primary: Baseline Mean Pain Score — 5.93; 6.08 units on a scale
N/A N=7 A Colonic Tube to Improve Bowel Function in Spinal Cord Injury
Constipation · Fecal Incontinence · Spinal Cord Injury
Primary: Change in Bowel QoL — -4.17; -3.65 units on a scale
Phase 3 N=758 Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
Opioid Dependence, on Agonist Therapy
Primary: Primary Endpoints of Retention in Treatment at Days 3 and 15 — 309; 302; 273; 269 participants